Montrium, a provider of cloud-based software solutions for the life sciences, announced its eTMF Connect trial master file solution is being used in a Phase III global post-traumatic stress disorder (PTSD) trial. The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research organization is advancing from its MAPP1, the first study carried out in Phase III, to a global confirmatory MAPP2 study to assess the safety and efficacy of MDMA-assisted psychotherapy for patients with PTSD.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.